A Phase Ib/II Study of Atezolizumab in Combination with Thiopurine Therapy in Patients with Metastatic Solid Tumors and Intermediate Tumor Mutational Burden.

doi:10.1158/2767-9764.CRC-26-0210

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

A Phase Ib/II Study of Atezolizumab in Combination with Thiopurine Therapy in Patients with Metastatic Solid Tumors and Intermediate Tumor Mutational Burden.

Cancer research communications - 1 Sept 2026

Secher Christine Federspiel, Højgaard Martin, Spanggaard Iben, Schmidt Ane Yde, Guo Yuliu, Robinson Luca, De Zio Daniela, Toksvang Linea N, Bagger Frederik Otzen, Schmiegelow Kjeld, Rohrberg Kristoffer S

Abstract excerpt

PURPOSE: The Thiopurine Enhanced Mutations for PD-1/Ligand-1 Efficacy (TEMPLE) study was a phase Ib/II trial evaluating the safety, tolerability, and efficacy of atezolizumab combined with thiopurine therapy in patients with metastatic solid tumors, aiming to increase tumor mutational burden (TMB) through single-nucleotide mismatching and neoepitope generation. PATIENTS AND METHODS: Phase Ib was an open-label,...

Read the complete abstract on PubMed

Topics

Humans
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
Female

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Neoplasms

Male

Mutation

Middle Aged

Aged

Adult

Progression-Free Survival

Neoplasm Metastasis

Source

Open in PubMed Open full text

Identifiers

PMID: 42647116
DOI: 10.1158/2767-9764.CRC-26-0210
PMCID: PMC13578206

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 25 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Phase Ib/II Study of Atezolizumab in Combination with Thiopurine Therapy in Patients with Metastatic Solid Tumors and Intermediate Tumor Mutational Burden.PMID 42647116Read ↗

TAPISTRY: A Phase II Study of Atezolizumab in Patients with Tumor Mutational Burden-High Tumors.Semantic proximity Read ↗

Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden.Semantic proximity Read ↗

Pan-cancer population pharmacokinetics and exposure-safety and -efficacy analyses of atezolizumab in patients with high tumor mutational burden.Semantic proximity Read ↗

Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial.Semantic proximity Read ↗

Response Rates to Anti-PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per Megabase.Semantic proximity Read ↗

Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumab.Semantic proximity Read ↗

Thiopurine 6TG treatment increases tumor immunogenicity and response to immune checkpoint blockade.Semantic proximity Read ↗

Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study.Semantic proximity Read ↗

Tislelizumab in previously treated, locally advanced unresectable/metastatic microsatellite instability-high/mismatch repair-deficient solid tumorsSemantic proximity Read ↗

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.Semantic proximity Read ↗

A phase 1 trial of the oral DNA methyltransferase inhibitor CC‐486 and the histone deacetylase inhibitor romidepsin in advanced solid tumorsSemantic proximity Read ↗

Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C-Mutated Tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.